Loading...
Loading...
In a report published Wednesday, Stifel analyst Stephen Willey reiterated a Buy rating on
Ophthotech Corp.OPHT, and raised the price target from $58.00 to $59.00.
In the report, Stifel noted, “P3 enrollment remains on track and the tivozantib licensing agreement creates some additional low-cost optionality. Increased $59 target (previously $58) reflects refinement of Novartis milestone payments. Remain Buy-rated.”
Ophthotech Corp. closed on Tuesday at 41.74.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in